Latest Breaking News On - Tissue specific therapeutics - Page 2 : vimarsana.com

Immix Biopharma Announces Dr Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical.

New yorkUnited statesColumbia universityNew york presbyterian hospitalCaelum biosciencesSuzanne lentzschLos angelesMike moyerIlya rachmanGabriel morrisCompany contactAmyloidosis programMyeloma steering committeeLentzsch coImmix biopharma incMyeloma working group

Immix Biopharma Announces Dr Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center Dr. Landau is a recognized thought.

Memorial sloan kettering cancer centerNew yorkUnited statesLos angelesHeather landauMike moyerGabriel morrisIlya rachmanAmyloidosis programExchange commissionCompany contactUniversity of coloradoNexcella incImmix biopharma incNexcella scientific advisory boardNexcella scientific advisory

Immix Biopharma Announces Dr Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

Immix Biopharma Announces Dr Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkMemorial sloan kettering cancer centerMike moyerIlya rachmanGabriel morrisLos angelesHeather landauAmyloidosis programUniversity of coloradoImmix biopharma incExchange commissionNexcella incNexcella scientific advisory boardImmix biopharmaNexcella scientific advisory

Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting

LOS ANGELES, July 25, 2023 Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. , today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for.

United statesPolina stepenskyLos angelesAlex loboInternational myeloma working groupImmix biopharma inc nasdaqDepartment of bone marrow transplantationInternational myeloma society annual meetingExchange commissionNexcella incCompany contactImmix biopharma incHadassah medical organizationGlobenewswire incMyeloma society annual meetingBone marrow transplantation

Immix Biopharma Subsidiary Nexcella Announces NXC-201

Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in Athens September 27-30, 2023.

United statesAlex loboLos angelesPolina stepenskyImmix biopharma incNexcella incInternational myeloma society annual meetingImmix biopharma inc nasdaqInternational myeloma working groupExchange commissionImmix biopharmaHadassah medical organizationBone marrow transplantationMultiple myelomaUniform response criteriaTissue specific therapeutics